报价延迟最少15分钟:2026/05/06 12:41 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.8 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.94/--
|
|
企业价值
851.89M
|
| 资产负债 |
|
每股账面净值
-1.75
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects. |
